Morphologic changes induced by gefitinib in primary patient AML blasts. May-Grünwald Giemsa staining of primary patient M3-AML blasts (patient 1) containing the t(15;17) and trisomy 8 treated in vitro for 3 days with (A) 0.01% DMSO and (B) 5 μM gefitinib, primary patient M4-AML blasts (patient 7) treated in vitro for 4 days with (C) 0.01% DMSO and (D) 2.5 μM gefitinib, and primary patient M1-AML blasts (patient 8) containing trisomy 8 treated in vitro for 7 days with (E) 0.01% DMSO and (F) 10 μM gefitinib. Images were acquired with an Olympus BH-2 microscope, × 100/1.25 magnification under oil, an Olympus Q-Color 5 digital camera, and Adobe Photoshop CS version 8.0 software.